Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA

INTRODUCTION: KRAS oncogene mutations ((MUT)KRAS) drive resistance to EGFR inhibition by providing alternative signaling as demonstrated in colo-rectal cancer. In non-small cell lung cancer (NSCLC), the efficacy of treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) depends on activating EGFR...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Del Re, Marzia, Tiseo, Marcello, Bordi, Paola, D'Incecco, Armida, Camerini, Andrea, Petrini, Iacopo, Lucchesi, Maurizio, Inno, Alessandro, Spada, Daniele, Vasile, Enrico, Citi, Valentina, Malpeli, Giorgio, Testa, Enrica, Gori, Stefania, Falcone, Alfredo, Amoroso, Domenico, Chella, Antonio, Cappuzzo, Federico, Ardizzoni, Andrea, Scarpa, Aldo, Danesi, Romano
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2016
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355124/
https://ncbi.nlm.nih.gov/pubmed/26799287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6957
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares